NK Cell Therapies
Activating the body’s natural killer cells for fast, powerful immune defense.
NK Cell Therapies | Workflow | Resources | FAQs | Contact Us
Supporting Breakthroughs in Natural Killer Cell Treatments
NK cell therapies harness the power of natural killer (NK) cells to recognize and eliminate diseased and cancer cells without prior sensitization, allowing for rapid and targeted responses. With a favorable safety profile and growing clinical momentum, NK cell therapies represent an exciting frontier in next-generation immunotherapy. R&D Systems reagents and analytical solutions support the development and manufacture of cell-based therapies – from preclinical cancer research to treatments for cancer patients.
Benefits of NK Cell Therapy Development
- Flexibility: NK cells can target cells and induce cell death without needing exact antigen presentation, for broad anti-tumor activity.
- Safety: NK therapies generally show reduced rates of cytokine release syndrome (CRS) and graft-versus-host disease (GVHD) compared to some T cell therapies.
- Allogeneic NK cell potential: Natural killer cells can be derived from cell lines or donors, including from umbilical cord blood, enabling standardized, ready-to-use treatments.
Overcome the Challenges of NK Cell Therapies
- Reproducibility and safety: High quality, consistent R&D Systems reagents enable reproducible results.
- Scalability: Our solutions scale seamlessly with your process, enabling your NK cell manufacturing to meet clinical demands.
- Regulatory support: We have submitted Drug Master Files (DMFs) for most GMP reagents, facilitating your IND submissions to the FDA and easing the transition to clinical manufacturing.
- Time and resource efficiency: Optimize timelines and control costs by partnering with experienced suppliers like R&D Systems, who understand the complexities of therapeutic development.
NK Cell Manufacturing Workflow Solutions
Advancing NK cell therapies requires robust tools to support engineering, expansion, and downstream functional assessment. R&D Systems supplies rigorously tested cytokines, growth factors, media, supplements and antibodies to support each phase of development. With dependable performance lot after lot, these solutions help scientists accelerate NK therapy development while maintaining confidence in the quality, safety and reproducibility of their results.
NK Cell Isolation
Antibody specificity is the basis for accurate and reproducible cell selection. Choosing the right antibodies will enable you to reliably isolate high purity NK cell populations.
- MagCellect™ Human NK Cell Isolation Kit
- Anti- CD3 and CD19 antibodies to confirm removal of T and B cells
NK Cell Genome Engineering
Genome engineering of NK cell lines enables precise modifications (gene knockouts, transgene insertions, and receptor engineering) to enhance specificity, persistence, and therapeutic potency. Developers are increasingly shifting from viral vectors to non‑viral approaches, such as TcBuster transposon system and electroporation‑based transfection, to improve safety while reducing manufacturing time and cost.
NK Cell Culture & Expansion
Human NK Cell Expansion Media
Animal-free, serum-free formulation for high fold expansion and killing capacity.
GMP Cytokines & Growth Factors
GMP cytokines, formatted to fit your workflow and ready for NK cell manufacturing.
GMP Recombinant Human Serum Albumin
Enhances cell expansion in a serum-free, clinical grade workflow.
GMP ProPak Cytokines
ProPak weldable bags provide GMP proteins, including interleukins, within a closed process format.
CellXVivo Human NK Cell Expansion Kit
Provides optimized reagents needed to induce ex vivo expansion of CD3-CD56+ NK cells.
NK Cell Activation Flow Cytometry Panel
Investigate the expression of intracellular proteins during NK cell activation.
The majority of NK cells found in peripheral blood can be characterized based on their expression of CD16 and CD56. NK cells are traditionally defined as CD16+CD56dim or CD16dimCD56+.
- Hematopoietic Lineage: CD45
- NK cells: NCAM-1/CD56
- NK cells for ADCC: Fc Gamma RIII (CD16)
- Pro-inflammatory NK cells: CD161
See a full list of NK cell markers.
To phenotype your NK cells, we offer highly validated monoclonal and recombinant monoclonal antibodies for NK cell surface proteins including the Natural Cytotoxicity Receptor (NCR) and Killer-Immunoglobulin-Like Receptors (KIR) families. R&D Systems multi-color FlowX Human NK Cell Phenotyping Flow Cytometry Kit has the reagents you need to streamline your flow cytometry panel design, including staining buffers and isotype controls.
| Marker | Clone | Fluorochrome |
| CD3 | UCHT1 | Alexa Fluor 405 |
| NCAM1/CD56 | 2524C | Alexa Fluor 647 |
| NKp30/NCR3 | 210845 | Alexa Fluor 488 |
| NKG2D/CD314 | 149810 | Alexa Fluor 700 |
| NKp46/NCR1 | 195314 | PE |
| Fc Gamma R III (CD16) | 245536 | PerCP |
Resources
Development and Manufacturing
- App Note: Scaling Up Non-Viral CAR-NK Manufacturing
- Pathway Map: NK Cell Receptors
- Tumor Microenvironment: Mechanisms of Tumor Invasion and Immunosuppression
Analysis
Potency
What types of NK cell therapies are being developed?
Scientists are advancing several types of immune cell therapies, including cytokine-activated NK cells, CAR-NK cell therapies related to CAR-T cell therapies, iPSC (induced pluripotent stem cell)-derived NK platforms, and therapies based on the NK-92. These approaches aim to improve the ability of NK cells to recognize and kill cell malignancies while maintaining a strong safety profile and minimizing side effects of oncology treatments. Though individualized (autologous) therapies are used, many programs focus on creating off-the-shelf treatments, enhancing persistence, and overcoming tumor-related immune suppression. As innate immune system research progresses, new gene editing and cell manufacturing strategies are expanding the potential of the cancer immunotherapy landscape.
NK cell therapies are being used as anti-cancer treatments. NK cancer therapy has been used to treat blood cancers, including acute myeloid leukemia (AML), B cell lymphoma, and bone marrow cancer such as multiple myeloma, though solid tumor cells are also increasingly under investigation, including melanoma, carcinoma, ovarian cancer, pancreatic cancer, and breast cancer.
What challenges do NK cell therapy developers face?
NK cell therapy developers face several important challenges as they move programs toward the clinic. Ensuring consistent cell quality, potency, and safety requires reliable reagents, robust expansion methods, and well-controlled manufacturing processes. Achieving NK cell functionality with sufficient persistence and cell activity in patients—especially in solid tumors—remains a scientific hurdle. Having sufficient cell populations to scale production into off-the-shelf formats while maintaining reproducibility adds further complexity. In addition, teams must navigate evolving regulatory requirements and generate strong clinical data to demonstrate durability and safety. Efficient workflows, scalable platforms, and experienced development partners are critical to advancing NK cell therapies successfully.
What should NK cell therapy developers consider when starting a therapeutic project?
NK cell therapy developers should begin by carefully defining their cell source, engineering strategy, and expansion approach, ensuring each step uses well-characterized, high-quality reagents and standardized processes. Early consideration of scalability, such as off-the-shelf potential, cryopreservation strategy, and GMP-ready manufacturing workflows, can help streamline the transition from research to clinical development. Teams should also evaluate persistence, tumor targeting, and resistance to immune suppression as part of early design. Regulatory planning, safety testing, and non-viral engineering platforms are critical to reducing risk and enabling efficient, cost-effective translation to the clinic.